Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 28 of 28 publications.

Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2-agonists. Int J Chron Obstruct Pulmon Dis. 2022 Aug 2;17:1715-33. doi: 10.2147/COPD.S363997

Rebordosa C, Plana E, Rubino A, Aguado J, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. A cohort study to evaluate the risk of hospitalisation for congestive heart failure associated with the use of aclidinium and other chronic obstructive pulmonary disease medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. 2021 May 31;16:1461-75. doi: 10.2147/COPD.S301624

Ardeshirrouhanifard S, An H, Goyal RK, Raji M, Segal J, Alexander GC, Mehta HB. Initiation and switching of direct oral anticoagulants among Medicare beneficiaries with cancer and atrial fibrillation. Poster presented at the 2021 American Heart Association, Epidemiology Scientific Session; May 2021. [abstract] Circulation. 2021 May 25; 143(Suppl 1):AP148.

Donohue IF, Bollu VK, Stull DE, Nelson LM, Williams VS, Stensland MD, Hanania NA. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. Int J Chron Obstruct Pulmon Dis. 2018 Feb 5;13:499-508.

Abdul-Jawad Altisent O, Puri R, Regueiro A, Chamandi C, Rodriguez-Gabella T, Del Trigo M, Campelo-Parada F, Couture T, Marsal JR, Cote M, Paradis JM, DeLarochellière R, Doyle D, Mohammadi S, Dumont E, Rodes-Cabau J. Predictors and association with clinical outcomes of the changes in exercise capacity after transcatheter aortic valve replacement. Circulation. 2017 Aug 15;136(7):632-43. doi: 10.1161/CIRCULATIONAHA.116.026349

Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017 Mar 24;2017(12):997-1008.

Schwab P, Dhamane AD, Hopson SD, Moretz C, Annavarapu S, Burslem K, Renda A, Kaila S. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2017 Feb 23;12:735-44. doi: 10.2147/COPD.S112256

Dhamane AD, Schwab P, Hopson S, Moretz C, Annavarapu S, Burslem K, Renda A, Kaila S. Association between adherence to medications for COPD and medications for other chronic conditions in COPD patients. Int J Chron Obstruct Pulmon Dis. 2016 Dec 22;12:115-22. doi: 10.2147/COPD.S114802

Raspa M, Sacco P, Candrilli SD, Bishop E, Petrillo J. Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist-utility index. J Intellect Disabil Res. 2016 Sep;60(9):844-55. doi: 10.1111/jir.12264

Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012 Jul 1;7:457-94.

Dalal AA, Demuro-Mercon C, Lewis S, Nelson L, Gilligan T, McLeod L. Validation of alternate modes of administration of the lung function questionnaire (LFQ) in subjects with smoking history. Int J Chron Obstruct Pulmon Dis. 2010 Dec 1;5:425-34.

Ferreira-Gonzalez I, Marsal JR, Ribera A, Permanyer-Miralda G, Garcia-Del Blanco B, Marti G, Cascant P, Martin-Yuste V, Brugaletta S, Sabate M, Alfonso F, Capote ML, De La Torre JM, Ruiz-Lera M, Sanmiguel D, Cardenas M, Pujol B, Baz JA, Iniguez A, Trillo R, Gonzalez-Bejar O, Casanova J, Sanchez-Gila J, Garcia-Dorado D. Background, incidence, and predictors of antiplatelet therapy discontinuation during the first year after drug-eluting stent implantation. Circulation. 2010 Sep 7;122(10):1017-25. doi: 10.1161/CIRCULATIONAHA.110.938290

Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation. 2002 Jan 1;106(23):2919-24.

Adams MR, Golden DL, Register TC, Anthony MS, Hodgin JB, Williams JK. The atheroprotective effect to dietary soy isoflavones in apolipoprotein E -/- mice requires the presence of estrogen receptor-a. Circulation. 2002;p.106.

Carnethon MR, Anthony MS, Cascio WE, Folsom AR, Evans GE, Liao D. Prospective association between hormone replacement therapy and the QT index. Circulation. 2001;104:II-792.

Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Gutthann S, Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation. 2000 Jun 6;101(22):2572-8.

Anthony MS, Clarkson TB, Evans GW. Estrogen-only versus estrogen + progestin replacement therapy: effects on coronary artery atherosclerosis extent and carotid artery intima-media thickness. Presented at the 40th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association; March 1, 2000. San Diego, CA. [abstract] Circulation. 2000; 101(6):714.

Williams K, Anthony MS, Andersen HL. A comparison of plant and mammalian estrogens on dilator and constrictor responses of atherosclerotic coronary arteries in postmenopausal monkeys. Circulation. 1998 Oct;98(Suppl I):I-463.

Clarkson TB, Anthony MS. Effect of hormone replacement therapy on internal carotid artery atherosclerosis on postmenopausal monkeys. Circulation. 1998;97:830.

Anthony MS, Clarkson TB. Comparison of soy phytoestrogens and conjugated equine estrogens on atherosclerosis progression on postmenopausal monkeys. Presented at the 38th Annual Conference on Cardiovascular Disease Epidemiology and Prevention; March 1998. Sante Fe, NM. [abstract] Circulation. 1998; 97:829.

Williams JK, Sukhova Gk, Anthony MS, Libby P. The cholesterol-lowering independent effects of pravastatin on the artery wall of monkeys. Circulation. 1997;96(Suppl I):I-607.

Anthony MS, Clarkson TB, Bullock BC. Soy protein versus soy phytoestrogens (isoflavones) in the prevention of coronary artery atherosclerosis of cynomolgus monkeys. Presented at the 69th Scientific Sessions of the American Heart Association; November 1996. New Orleans, LA. [abstract] Circulation. 1996; 94(Suppl I):I-265.

Moran CM, Fleming AD, Sutherland GR, Anderson T, McDicken WN. An evaluation of the properties of myocardial color Doppler energy mapping using test phantoms. Circulation. 1995 Oct 15;92(8):71.

Kaplan JR, Clarkson TB, Adams MR, Anthony MS, Manuck SB, Morgan TM. Oral contraceptives inhibit atherogenesis in female monkeys at high risk due to social subordination. Circulation. 1995;92(Suppl I):I-627.

Honoré EK, Williams JK, Anthony MS. Enhancement of coronary vasodilation by soy phytoestrogens. Circulation. 1995;92(Suppl I):I-349.

Anthony MS, Burke GL, Hughes CLJr, Clarkson TB. Does soy supplementation improve Coronary Heart Disease (CHD) risk? Presented at the 35th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, American Heart Association; March 1995. San Antonio, TX. [abstract] Circulation. 1995; 91:925.

Anthony MS, Clarkson TB, Hughes CL. Plant and mammalian estrogen effects on plasma lipids of female monkeys. Presented at the 67th Annual Scientific Sessions, American Heart Association; November 1994. Dallas, TX. [abstract] Circulation. 1994; 90:I-235.

Anthony MS, Crouse JR. Heterogeneity in plasma lipoprotein response to dietary fish oil. Presented at the 61st Scientific Sessions of the American Heart Association; November 1988. Washington, DC. [abstract] Circulation. 1988; 78(Suppl II):571. Previously presented at the 8th International Symposium on Atherosclerosis.